Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2018

14.11.2017 | Original Article

Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer

verfasst von: Geoffrey M. Kozak, Jeffrey D. Epstein, Sandeep P. Deshmukh, Benjamin B. Scott, Scott W. Keith, Harish Lavu, Charles J. Yeo, Jordan M. Winter

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Localized and unresectable pancreatic ductal adenocarcinoma (PDA) comprises one third of new diagnoses and includes borderline resectable (BR) and locally advanced (LA) unresectable disease. In a cohort of patients who were treated and followed at a single institution, we assessed clinical and radiographic predictors of outcome.

Methods

The study included 69 consecutive patients with BR or LA PDA. Serial imaging studies were reviewed by both a pancreatic surgeon and a radiologist for vascular abutment or encasement by cancer, and they were recorded.

Results

The cohort included 25 patients with BR and 44 patients with LA PDA, with median overall survivals (OS) of 15 and 14 months, respectively (p = 0.802). Fifteen patients were resected (22%), with a median OS of 21 months from diagnosis (HR 2.50, p = 0.006) and 13 months from resection. Median OS from diagnosis was 33 months in patients without lymph node metastases at resection (n = 10), but just 17 months with lymph node metastases (n = 5, HR = 8.95, p = 0.011). There were 12 two-year survivors in the total cohort (17%), and seven of them never underwent resection. First-line treatments consisted of gemcitabine (n = 13), modern first-line combinations (FOLFIRNOX or gemcitabine/nab-paclitaxel, n = 24), or alternative multi-agent therapies (n = 32); there were no statistical differences between treatment subgroups (OS of 10, 13, and 16 months, respectively). Common hepatic artery (CHA) abutment or encasement at diagnosis was associated with poor survival (adjusted hazard ratio, CHA abutment = 2.47 (p = 0.015) and CHA encasement = 2.16 (p = 0.036)).

Conclusion

In this cohort, common hepatic arterial abutment or encasement and residual lymph node disease at resection portended a particularly poor outcome in patients with localized, unresectable PDA.
Literatur
1.
Zurück zum Zitat Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA Cancer J Clin, 2016. 66(1): p. 7–30.CrossRefPubMed Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA Cancer J Clin, 2016. 66(1): p. 7–30.CrossRefPubMed
2.
Zurück zum Zitat Varadhachary, G.R., et al., Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol, 2006. 13(8): p. 1035–46.CrossRefPubMed Varadhachary, G.R., et al., Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol, 2006. 13(8): p. 1035–46.CrossRefPubMed
3.
Zurück zum Zitat Slavin, J., et al., The future of surgery for pancreatic cancer. Annals of oncology, 1999. 10(suppl 4): p. S285-S290.CrossRef Slavin, J., et al., The future of surgery for pancreatic cancer. Annals of oncology, 1999. 10(suppl 4): p. S285-S290.CrossRef
4.
Zurück zum Zitat Katz, M.H., et al., Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg, 2008. 206(5): p. 833–46; discussion 846-8.CrossRefPubMed Katz, M.H., et al., Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg, 2008. 206(5): p. 833–46; discussion 846-8.CrossRefPubMed
5.
Zurück zum Zitat Tempero, M.A., Malafa, M.P., Al-Hawary, M., Asbun, H., Bain, A., Behrman, S.W., Benson, A.B., Binder, E., Cardin, D.B., Cha, C., Chiorean, E.G., Chung, V., Czito, B., Dillhoff, M., Dotan, E., Ferrone, C.R., Hardacre, J., Hawkins, W.J., Herman, J., Ko, A.H, Komanduri, S., Koong, A., LoConte, N., Lowy, A.M, Moravek, C., Nakakura, E.K, O'Reilly, E.M, Obando, J., Reddy, S., Scaife C., Thayer, S., Weekes, C.D, Wolff, R.A, Wolpin, B.M, Burns, J., Darlow. S. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw, 2017. 15(8): p. 1028–61. Tempero, M.A., Malafa, M.P., Al-Hawary, M., Asbun, H., Bain, A., Behrman, S.W., Benson, A.B., Binder, E., Cardin, D.B., Cha, C., Chiorean, E.G., Chung, V., Czito, B., Dillhoff, M., Dotan, E., Ferrone, C.R., Hardacre, J., Hawkins, W.J., Herman, J., Ko, A.H, Komanduri, S., Koong, A., LoConte, N., Lowy, A.M, Moravek, C., Nakakura, E.K, O'Reilly, E.M, Obando, J., Reddy, S., Scaife C., Thayer, S., Weekes, C.D, Wolff, R.A, Wolpin, B.M, Burns, J., Darlow. S. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw, 2017. 15(8): p. 1028–61.
6.
Zurück zum Zitat Kim, H.J., et al., Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg, 2002. 6(5): p. 763–9.CrossRefPubMed Kim, H.J., et al., Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg, 2002. 6(5): p. 763–9.CrossRefPubMed
7.
Zurück zum Zitat Winter, J.M., et al., 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg, 2006. 10(9): p. 1199–210; discussion 1210-1.CrossRefPubMed Winter, J.M., et al., 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg, 2006. 10(9): p. 1199–210; discussion 1210-1.CrossRefPubMed
8.
Zurück zum Zitat Siegel, R.L, Miller, K.D, Fedewa, S.A, Ahnen, D.J, Meester, R.G.S, Barzi, A., Jemal, A. Colorectal cancer statistics. CA Cancer J Clin, 2017. 67(3): p. 177-93. Siegel, R.L, Miller, K.D, Fedewa, S.A, Ahnen, D.J, Meester, R.G.S, Barzi, A., Jemal, A. Colorectal cancer statistics. CA Cancer J Clin, 2017. 67(3): p. 177-93.
9.
Zurück zum Zitat Hosein, P.J., et al., A retrospective study of neoadjuvant FOLFIRINOX in unresectable osr borderline-resectable locally advanced pancreatic adenocarcinoma. BMC cancer, 2012. 12(1): p. 199.CrossRefPubMedPubMedCentral Hosein, P.J., et al., A retrospective study of neoadjuvant FOLFIRINOX in unresectable osr borderline-resectable locally advanced pancreatic adenocarcinoma. BMC cancer, 2012. 12(1): p. 199.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Evans, D.B., et al., Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol, 2008. 26(21): p. 3496–502.CrossRefPubMed Evans, D.B., et al., Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol, 2008. 26(21): p. 3496–502.CrossRefPubMed
11.
Zurück zum Zitat Bickenbach, K., et al., Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Annals of surgical oncology, 2012. 19(5): p. 1663–1669.CrossRefPubMed Bickenbach, K., et al., Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Annals of surgical oncology, 2012. 19(5): p. 1663–1669.CrossRefPubMed
12.
Zurück zum Zitat Blazer, M., et al., Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Annals of surgical oncology, 2015. 22(4): p. 1153–1159.CrossRefPubMed Blazer, M., et al., Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Annals of surgical oncology, 2015. 22(4): p. 1153–1159.CrossRefPubMed
13.
Zurück zum Zitat Khushman, M.D, et al., Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology, 2015. 15(6): p. 667–673.CrossRefPubMed Khushman, M.D, et al., Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology, 2015. 15(6): p. 667–673.CrossRefPubMed
14.
Zurück zum Zitat Petrelli, F., et al., FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas, 2015. 44(4): p. 515–521.CrossRefPubMed Petrelli, F., et al., FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas, 2015. 44(4): p. 515–521.CrossRefPubMed
15.
Zurück zum Zitat Boone, B.A., et al., Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. Journal of surgical oncology, 2013. 108(4): p. 236–241.CrossRefPubMed Boone, B.A., et al., Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. Journal of surgical oncology, 2013. 108(4): p. 236–241.CrossRefPubMed
16.
Zurück zum Zitat Peddi, P.F., et al., Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. Journal of the Pancreas, 2012. 13(5): p. 497–501.PubMed Peddi, P.F., et al., Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. Journal of the Pancreas, 2012. 13(5): p. 497–501.PubMed
17.
Zurück zum Zitat Fong, Z.V., et al., Preoperative imaging for resectable periampullary cancer: clinicopathologic implications of reported radiographic findings. Journal of Gastrointestinal Surgery, 2013. 17(6): p. 1098–1106.CrossRefPubMed Fong, Z.V., et al., Preoperative imaging for resectable periampullary cancer: clinicopathologic implications of reported radiographic findings. Journal of Gastrointestinal Surgery, 2013. 17(6): p. 1098–1106.CrossRefPubMed
18.
Zurück zum Zitat Eisenhauer, E., et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer, 2009. 45(2): p. 228–247.CrossRefPubMed Eisenhauer, E., et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer, 2009. 45(2): p. 228–247.CrossRefPubMed
19.
Zurück zum Zitat Wasif, N., et al., Association of distance traveled for surgery with short-and long-term cancer outcomes. Annals of surgical oncology, 2016. 23(11): p. 3444–3452.CrossRefPubMed Wasif, N., et al., Association of distance traveled for surgery with short-and long-term cancer outcomes. Annals of surgical oncology, 2016. 23(11): p. 3444–3452.CrossRefPubMed
20.
Zurück zum Zitat Heinemann, V., Haas, M., Boeck, S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol, 2013. 24(10): p. 2484–92. Heinemann, V., Haas, M., Boeck, S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol, 2013. 24(10): p. 2484–92.
21.
Zurück zum Zitat Coveler, A.L., Herman, J.M., Simeone, D.M., Chiorean, E.G. Localized pancreatic cancer: multidisciplinary management. In American Society of Clinical Oncology educational book. American Society ofClinical Oncology. Meeting, 2016. 35: pp. e217–26. Coveler, A.L., Herman, J.M., Simeone, D.M., Chiorean, E.G. Localized pancreatic cancer: multidisciplinary management. In American Society of Clinical Oncology educational book. American Society ofClinical Oncology. Meeting, 2016. 35: pp. e217–26.
22.
Zurück zum Zitat Loehrer, A.P. and C.R. Ferrone, Treatment of locally advanced pancreatic ductal adenocarcinoma. Digestive surgery, 2016. 33(4): p. 343–350.CrossRefPubMed Loehrer, A.P. and C.R. Ferrone, Treatment of locally advanced pancreatic ductal adenocarcinoma. Digestive surgery, 2016. 33(4): p. 343–350.CrossRefPubMed
23.
Zurück zum Zitat Hackert, T., A. Ulrich, and M.W. Büchler, Borderline resectable pancreatic cancer. Cancer letters, 2016. 375(2): p. 231–237.CrossRefPubMed Hackert, T., A. Ulrich, and M.W. Büchler, Borderline resectable pancreatic cancer. Cancer letters, 2016. 375(2): p. 231–237.CrossRefPubMed
24.
Zurück zum Zitat Tang, K., et al., Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. Pancreatology, 2016. 16(1): p. 28–37.CrossRefPubMed Tang, K., et al., Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. Pancreatology, 2016. 16(1): p. 28–37.CrossRefPubMed
25.
Zurück zum Zitat Suker, M., et al., FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. The Lancet Oncology, 2016. 17(6): p. 801–810.CrossRefPubMedPubMedCentral Suker, M., et al., FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. The Lancet Oncology, 2016. 17(6): p. 801–810.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Huguet, F., et al., Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. Journal of Clinical Oncology, 2009. 27(13): p. 2269–2277.CrossRefPubMed Huguet, F., et al., Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. Journal of Clinical Oncology, 2009. 27(13): p. 2269–2277.CrossRefPubMed
27.
Zurück zum Zitat Chauffert, B., et al., Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Annals of oncology, 2008. 19(9): p. 1592–1599.CrossRefPubMed Chauffert, B., et al., Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Annals of oncology, 2008. 19(9): p. 1592–1599.CrossRefPubMed
28.
Zurück zum Zitat Huguet, F., et al., Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. Journal of Clinical Oncology, 2007. 25(3): p. 326–331.CrossRefPubMed Huguet, F., et al., Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. Journal of Clinical Oncology, 2007. 25(3): p. 326–331.CrossRefPubMed
29.
Zurück zum Zitat Hammel, P., et al., Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. Jama, 2016. 315(17): p. 1844–1853.CrossRefPubMed Hammel, P., et al., Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. Jama, 2016. 315(17): p. 1844–1853.CrossRefPubMed
30.
Zurück zum Zitat Von Hoff, D.D., et al., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 2013. 369(18): p. 1691–703.CrossRef Von Hoff, D.D., et al., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 2013. 369(18): p. 1691–703.CrossRef
31.
Zurück zum Zitat Conroy, T., et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011. 364(19): p. 1817–25.CrossRefPubMed Conroy, T., et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011. 364(19): p. 1817–25.CrossRefPubMed
32.
Zurück zum Zitat Crane, C.H., et al., Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. Journal of Clinical Oncology, 2011. 29(22): p. 3037–3043.CrossRefPubMedPubMedCentral Crane, C.H., et al., Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. Journal of Clinical Oncology, 2011. 29(22): p. 3037–3043.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Sathyamurthy, A., et al., Pancreatic Cancer Survival Outcomes at a Tertiary Medical Center Based on Sex and Geographic Location. Southern medical journal, 2016. 109(11): p. 718.PubMed Sathyamurthy, A., et al., Pancreatic Cancer Survival Outcomes at a Tertiary Medical Center Based on Sex and Geographic Location. Southern medical journal, 2016. 109(11): p. 718.PubMed
34.
Zurück zum Zitat Chen, J., et al., Racial differences in the use of cardiac catheterization after acute myocardial infarction. New England Journal of Medicine, 2001. 344(19): p. 1443–1449.CrossRefPubMed Chen, J., et al., Racial differences in the use of cardiac catheterization after acute myocardial infarction. New England Journal of Medicine, 2001. 344(19): p. 1443–1449.CrossRefPubMed
35.
Zurück zum Zitat Epstein, A.M., Ayanian, J.Z. Racial disparities in medical care. Mass Medical Soc, 2016. 2001: p. 1471–73. Epstein, A.M., Ayanian, J.Z. Racial disparities in medical care. Mass Medical Soc, 2016. 2001: p. 1471–73.
36.
Zurück zum Zitat Burris, H.A., 3rd, et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997. 15(6): p. 2403–13.CrossRefPubMed Burris, H.A., 3rd, et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997. 15(6): p. 2403–13.CrossRefPubMed
Metadaten
Titel
Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer
verfasst von
Geoffrey M. Kozak
Jeffrey D. Epstein
Sandeep P. Deshmukh
Benjamin B. Scott
Scott W. Keith
Harish Lavu
Charles J. Yeo
Jordan M. Winter
Publikationsdatum
14.11.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2018
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-017-3595-7

Weitere Artikel der Ausgabe 2/2018

Journal of Gastrointestinal Surgery 2/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.